SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

NCT03661125 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease Psychosis

Interventions

DRUG: Saracatinib
DRUG: Placebo Oral Tablet

Sponsor

King's College London

Collaborators

[object Object]
[object Object]